Kratom Safety and Toxicology in Public Health Context: Comprehensive Review Addresses Regulatory Gaps

Why it matters

This comprehensive review from experts at Johns Hopkins, University of Florida, and Thomas Jefferson University synthesizes over 200 recent research papers on kratom pharmacology, epidemiology, and safety. It provides an evidence-based foundation for federal kratom regulation and addresses key controversies about abuse potential and overdose risk.

The big picture

Kratom is a botanical product with diverse, complex pharmacology affecting multiple neurotransmitter systems—not primarily an opioid despite partial mu-receptor agonism. The review reveals that kratom's abuse potential is lower than opioids, stimulants, or alcohol; treatment-seeking for kratom use disorder is rare compared to other substances; and kratom-associated deaths almost always involve other substances, making attribution difficult. Most kratom users in the U.S. report health and wellbeing motivations rather than recreational use.

Key findings

• 1.7–1.8 million past-year kratom users estimated in U.S.; lifetime prevalence may reach 3–6 million
• Mitragynine (kratom's major alkaloid) acts as a partial opioid agonist at mu receptors but also affects adrenergic, serotonergic, dopaminergic, and adenosinergic systems
• Respiratory depression—the primary cause of opioid overdose—is NOT a significant risk from kratom due to weak beta-arrestin recruitment at opioid receptors
• Animal studies show mitragynine has lower reinforcing effects than morphine and reduces heroin self-administration
• Most kratom-associated deaths involve multiple substances; comprehensive toxicology reveals other lethal drugs in all cases examined
• Withdrawal is generally mild-to-moderate when it occurs; animal studies show opioid medications can treat kratom withdrawal
• 66.7% of regular kratom users meet mild DSM-5 use disorder criteria, mostly reflecting tolerance and withdrawal, not hazardous use or social impairment
• No lethal dose of kratom has been established in humans; animal studies with doses 10-100x human intake found no respiratory depression

What they say

"The most serious risks of kratom—life-threatening sickness and overdose death—may be co-ingested drugs, contaminants (e.g., salmonella), and adulterants (e.g., opioids including fentanyl and methamphetamine). We conclude with recommendations for kratom regulation and research priorities needed to address current policy and knowledge gaps around this increasingly used botanical product." — Jack E. Henningfield et al., Johns Hopkins

Bottom line

Kratom's complex pharmacology and low overdose risk profile support evidence-based FDA regulation of product quality and labeling rather than scheduling; research-informed regulatory standards can protect public health while preserving access.